| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.13 | 0.5 |
| mRNA | Salubrinal | GDSC1000 | pan-cancer | AAC | 0.042 | 0.5 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.5 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.043 | 0.5 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.5 |